Companies › Chengdu Qingshan Likang Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| amino acid (15) peritoneal dialysis solution Peritoneal dialysis solution containing 15 essential and non-essential amino acids | – | Phase 4 | End Stage Renal Disease (ESRD) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06597201 | amino acid (15) peritoneal dialysis solution | Phase 4 | End Stage Renal Disease (ESRD) | Genitourinary | Jun 2025 |
No annotated target.
–
Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience Hope Medicine (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.